Parsippany, New Jersey / Brussels, October 29, 2025 — Zoetis Inc. today announced that the European Commission has granted marketing authorisation for its new product Portela® (relfovetmab), the first long-acting monoclonal antibody (mAb) therapy designed to alleviate pain associated with osteoarthritis in cats with a single injection every three months.
Science Significance
Portela® uses a felinised mAb targeting the nerve growth factor (NGF) pathway — a critical mediator of pain and joint inflammation — enabling a novel mechanism of action in feline osteoarthritis (OA) management. In a nine-month European field trial, cats treated with relfovetmab demonstrated consistent reductions in pain and mobility impairment, even in animals with early-stage kidney disease, thereby representing a meaningful advancement in veterinary analgesic science by extending dosing interval and improving quality of life for companion animals.
Regulatory Significance
The marketing authorisation follows the positive opinion issued by the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) and reflects a robust benefit-risk assessment of safety, efficacy and dosing convenience. This milestone highlights the evolving regulatory landscape for veterinary biologics and reinforces that advanced therapeutic modalities in animals — such as mAbs — are subject to sophisticated approval pathways, with implications for quality control, manufacturing standards, post-approval pharmacovigilance and cGxP compliance in animal-health products.
Business Significance
Advertisement
For Zoetis, the approval of Portela® strengthens its feline pain-management portfolio and opens the potential for commercial rollout across the European Union in 2026. The extended dose-interval model offers a premium positioning in the animal-health market and may increase customer adherence, competitive differentiation and lifetime value per patient (cat). As companion-animal health continues to grow globally, this strategic move positions the company to capitalise on the intersection of biologics and pet-care trends.
Patients’ Significance
While the “patients” in this case are companion cats, the impact is substantial: feline OA affects up to ~40 % of aging cats and is frequently under-diagnosed. The availability of a three-month injectable treatment reduces the burden of frequent dosing, improves mobility and comfort, and enhances the human-animal relationship by reducing chronic pain and its downstream effects on behaviour, mobility and wellbeing. Pet-owners and veterinarians now have access to a more convenient, long-acting therapeutic option.
Policy Significance
This approval underscores broader policy shifts in animal-health regulation, such as the push for innovation in veterinary biologics, harmonised standards for quality and safety, and recognition of high-value therapeutic advances for companion animals. It also highlights how regulatory frameworks (e.g., EU Regulation 2019/6) are accommodating advanced therapies for animals, which may influence future policy around reimbursement, companion-animal health standards and One-Health intersections.
In sum, Zoetis’s EU approval for Portela® (relfovetmab) marks a landmark event in veterinary biologic therapy — combining cutting-edge mAb science, regulatory innovation and commercial strategy to deliver long-acting relief for cats with osteoarthritis. For stakeholders in animal health, cGxP, biologics manufacturing and regulatory affairs, this development offers a clear example of how rigorous science meets stringent regulation and business opportunity to improve animal welfare and set new standards in companion-animal care.
Source: Zoetis Inc. press release
